Literature DB >> 14638763

Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide.

Tamika Burns1, Zhaojing Zhong, Michael Steinitz, Liise-anne Pirofski.   

Abstract

Pneumococcal capsular polysaccharide (PS) vaccines induce type-specific immunoglobulin M (IgM), IgG, and IgA. Type-specific IgG to the PS is sufficient to confer protection against the homologous serotype of the pneumococcus, but the efficacies of type-specific IgM and IgA are less well understood. We examined the in vitro activities and efficacies in mice of two human monoclonal antibodies (MAbs) to type 8 PS, NAD (IgA) and D11 (IgM). MAb-mediated opsonophagocytic killing was evaluated after coculture of type 8 pneumococci with human polymorphonuclear cells (PMNs), type-specific or control MAbs, and human complement sources. The effects of the MAbs on PMN interleukin-8 (IL-8) and IL-6 secretion were determined in supernatants from cocultures containing pneumococci and PMNs by enzyme-linked immunosorbent assay. MAb efficacy was determined in an intratracheal model of type 8 infection in mice with classical complement pathway deficiency. Both MAbs were protective in 100% of infected mice. Neither MAb promoted a significant amount of killing of type 8 pneumococci compared to its isotype control MAb. Both type-specific MAbs mediated complement-dependent modulation of PMN IL-8 secretion, with increased secretion at effector/target (E:T) ratios of 500:1 and 50:1 and reduced secretion at 1:5. Trypan blue staining revealed that PMNs cocultured with D11 were less viable at an E:T ratio of 1:5 than PMNs cocultured with the control MAb. PMN IL-6 secretion was increased by both type-specific and control MAbs. These results suggest that certain type-specific IgM and IgAs might contribute to host defense by modulation of the inflammatory response to pneumococci.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638763      PMCID: PMC308885          DOI: 10.1128/IAI.71.12.6775-6783.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  A pneumococcal protein that elicits interleukin-8 from pulmonary epithelial cells.

Authors:  M Madsen; Y Lebenthal; Q Cheng; B L Smith; M K Hostetter
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

2.  Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Alexander H Lucas; Donald C Reason
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 3.  Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies.

Authors:  Y M Deo; R F Graziano; R Repp; J G van de Winkel
Journal:  Immunol Today       Date:  1997-03

Review 4.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

6.  Quantitation of blood lymphocytes secreting antibodies to pneumococcal polysaccharides after in vivo antigenic stimulation.

Authors:  C Heilmann; F K Pedersen
Journal:  Scand J Immunol       Date:  1986-02       Impact factor: 3.487

7.  Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera.

Authors:  M E Rodriguez; W L van der Pol; L A Sanders; J G van de Winkel
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

8.  Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.

Authors:  Y H Su; X T Yan; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule.

Authors:  G A Jarvis; J M Griffiss
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

10.  Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood.

Authors:  M J Schultz; P Speelman; S Zaat; S J van Deventer; T van der Poll
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  17 in total

Review 1.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

2.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

4.  Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.

Authors:  Tamika Burns; Maria Abadi; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells.

Authors:  Johanna Rivera; Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.

Authors:  Sarah Weber; Haijun Tian; Nico van Rooijen; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

7.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

8.  Feasibility of radioimmunotherapy of experimental pneumococcal infection.

Authors:  E Dadachova; T Burns; R A Bryan; C Apostolidis; M W Brechbiel; J D Nosanchuk; A Casadevall; L Pirofski
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Systemic disease during Streptococcus pneumoniae acute lung infection requires 12-lipoxygenase-dependent inflammation.

Authors:  Beth A McCormick; John M Leong; Rudra Bhowmick; Nang Maung; Bryan P Hurley; Elsa Bou Ghanem; Karsten Gronert
Journal:  J Immunol       Date:  2013-10-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.